Last reviewed · How we verify

pegylated IFN alfa-2b plus ribavirin — Competitive Intelligence Brief

pegylated IFN alfa-2b plus ribavirin (pegylated IFN alfa-2b plus ribavirin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Hepatology.

marketed Antiviral combination therapy Interferon-alpha receptor (IFNAR); hepatitis C virus RNA-dependent RNA polymerase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

pegylated IFN alfa-2b plus ribavirin (pegylated IFN alfa-2b plus ribavirin) — National Taiwan University Hospital. Pegylated interferon alfa-2b activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
pegylated IFN alfa-2b plus ribavirin TARGET pegylated IFN alfa-2b plus ribavirin National Taiwan University Hospital marketed Antiviral combination therapy Interferon-alpha receptor (IFNAR); hepatitis C virus RNA-dependent RNA polymerase
Pegylated interferon alfa-2a + Ribavirin Pegylated interferon alfa-2a + Ribavirin University of California, San Francisco marketed Antiviral combination therapy Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
Peg-IFN + RBV Peg-IFN + RBV National Taiwan University Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Ribavirin, Peg interferon alfa 2b Ribavirin, Peg interferon alfa 2b Brooke Army Medical Center marketed Antiviral combination therapy HCV RNA-dependent RNA polymerase; interferon-alpha receptor
E: Peg-interferon alpha-2a & Ribavirin E: Peg-interferon alpha-2a & Ribavirin Kaohsiung Medical University Chung-Ho Memorial Hospital marketed Antiviral combination therapy Interferon-alpha receptor; viral RNA-dependent RNA polymerase
F: Peg-interferon alpha-2a & Ribavirin F: Peg-interferon alpha-2a & Ribavirin Kaohsiung Medical University Chung-Ho Memorial Hospital marketed Antiviral combination therapy Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
Peg-IFN + WB RBV for 16 weeks Peg-IFN + WB RBV for 16 weeks National Taiwan University Hospital marketed Antiviral combination therapy Interferon-alpha receptor; HCV RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

  1. Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
  2. National Taiwan University Hospital · 6 drugs in this class
  3. Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
  4. Hepatitis Resource Network · 1 drug in this class
  5. Hospices Civils de Lyon · 1 drug in this class
  6. MTI Medical Private Limited, Pakistan · 1 drug in this class
  7. Pacific Health Foundation · 1 drug in this class
  8. RedHill Biopharma Limited · 1 drug in this class
  9. Sherief Abd-Elsalam · 1 drug in this class
  10. The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pegylated IFN alfa-2b plus ribavirin — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-ifn-alfa-2b-plus-ribavirin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: